{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:17:53Z","timestamp":1783689473201,"version":"3.55.0"},"reference-count":30,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Introduction: Neovascular age-related macular degeneration (nAMD) is one of the leading causes of severe visionloss among older adults. This condition impairs patients\u2019 quality of life and imposes a significant economic burdenon the healthcare system. This study aims to determine the difference in direct healthcare cost (DHC) afterswitching the current pharmacological treatment in patients with nAMD, under a treat-and-extend regimen, tofaricimab.Methods: Treatment interval data obtained after switching to faricimab in 225 eyes with nAMD was used tocalculate total DHC in comparison with the theoretical DHC had if patients remained on their previous treatment(drug and treatment interval). An \u201coptimal responder\u201d was defined as a patient whose interval between intravitalinjections was extended by more than 8 weeks relative to the baseline treatment interval.Results: The theoretical DHC of treatment for this series of nAMD eyes would have been \u20ac2,351,241.90, comparedwith an actual DHC after switching to faricimab of \u20ac1,718,015.83, representing a saving of \u20ac633,226.06for 225 eyes. The mean theoretical DHC would have been \u20ac10,449.96 \u00b1 4,340.18 (from 1,423.75 to 23,695.20),compared with a mean actual total cost of \u20ac7,635.62 \u00b1 2,465.07 (from 2,571.88 to 15,431.28). The mean actualDHC was \u20ac8,499.74 \u00b1 2,678.42 in the \u201cnon-optimal responder\u201d group versus \u20ac6,593.59 \u00b1 1,674.91 in the \u201coptimalresponder\u201d group (p &lt; 0.001).Conclusion: Switching to faricimab in patients with nAMD on a treat-and-extend regimen with a treatment intervalof less than 12 weeks resulted in a significant reduction in total DHC, particularly in the \u201coptimal responder\u201dgroup.<\/jats:p>","DOI":"10.33393\/grhta.2026.3800","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:31:43Z","timestamp":1783686703000},"page":"185-191","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practice"],"prefix":"10.33393","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1105-9265","authenticated-orcid":false,"given":"Jorge","family":"Ruiz-Medrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariluz","family":"Puertas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3921-0772","authenticated-orcid":false,"given":"Mar\u00eda","family":"Hinojosa-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-1773","authenticated-orcid":false,"given":"Carlota","family":"Moreno-Alboran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9636-0788","authenticated-orcid":false,"given":"Jos\u00e9 M\u00aa","family":"Ruiz-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"20124","doi-asserted-by":"crossref","unstructured":"Mehta S. Age-related macular degeneration. Prim Care. 2015;42(3):377-391. https:\/\/doi.org\/10.1016\/j.pop.2015.05.009 PMID:26319344","DOI":"10.1016\/j.pop.2015.05.009"},{"key":"20125","doi-asserted-by":"crossref","unstructured":"Fleckenstein M, Keenan TDL, Guymer RH, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31. https:\/\/doi.org\/10.1038\/s41572-021-00265-2 PMID:33958600","DOI":"10.1038\/s41572-021-00265-2"},{"key":"20126","doi-asserted-by":"crossref","unstructured":"Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. 2017;124(12):1753-1763. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.035 PMID:28712657","DOI":"10.1016\/j.ophtha.2017.05.035"},{"key":"20127","doi-asserted-by":"crossref","unstructured":"Cheng S, Zhang S, Huang M, et al. Treatment of neovascular age-related macular degeneration with anti-vascular endothelial growth factor drugs: progress from mechanisms to clinical applications. Front Med (Lausanne). 2024;11:1411278. https:\/\/doi.org\/10.3389\/fmed.2024.1411278 PMID:39099595","DOI":"10.3389\/fmed.2024.1411278"},{"key":"20128","doi-asserted-by":"crossref","unstructured":"Ricci F, Bandello F, Navarra P, et al. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020;21(21):8242. https:\/\/doi.org\/10.3390\/ijms21218242 PMID:33153227","DOI":"10.3390\/ijms21218242"},{"key":"20129","doi-asserted-by":"crossref","unstructured":"Boyle J, Vukicevic M, Koklanis K, et al. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127-140. https:\/\/doi.org\/10.1080\/13548506.2016.1274040 PMID:28064517","DOI":"10.1080\/13548506.2016.1274040"},{"key":"20130","doi-asserted-by":"crossref","unstructured":"Varano M, Eter N, Winyard S, et al. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clin Ophthalmol. 2015;9:2243-2250. https:\/\/doi.org\/10.2147\/OPTH.S92548 PMID:26664038","DOI":"10.2147\/OPTH.S92548"},{"key":"20131","doi-asserted-by":"crossref","unstructured":"J\u00f8rstad \u00d8K, Steffensen LA, Eriksen K, et al. Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway. Acta Ophthalmol. 2020;98(8):774-779. https:\/\/doi.org\/10.1111\/aos.14177 PMID:31264363","DOI":"10.1111\/aos.14177"},{"key":"20132","doi-asserted-by":"crossref","unstructured":"Kristiansen IS, Haugli Br\u00e5ten R, J\u00f8rstad \u00d8K, et al. Intravitreal therapy for retinal diseases in Norway 2011-2015. Acta Ophthalmol. 2020;98(3):279-285. https:\/\/doi.org\/10.1111\/aos.14262 PMID:31587508","DOI":"10.1111\/aos.14262"},{"key":"20133","doi-asserted-by":"crossref","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1 PMID:25104651","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"20134","doi-asserted-by":"crossref","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144-1167. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305702 PMID:25136079","DOI":"10.1136\/bjophthalmol-2014-305702"},{"key":"20135","doi-asserted-by":"crossref","unstructured":"Ruiz-Moreno JM, Arias-Barquet L, Armad\u00e1-Maresca F, et al. Gu\u00edas de pr\u00e1ctica cl\u00ednica de la SERV: tratamiento de la degeneraci\u00f3n macular asociada a la edad (DMAE) exudativa. Arch Soc Esp Oftalmol. 2009;84(7):333-344. https:\/\/doi.org\/10.4321\/S0365-66912009000700004 PMID:19658051","DOI":"10.4321\/S0365-66912009000700004"},{"key":"20136","doi-asserted-by":"crossref","unstructured":"Reitan G, Kjellevold Haugen IB, Andersen K, Bragadottir R, Bindesb\u00f8ll C. Through the Eyes of Patients: Understanding Treatment Burden of Intravitreal Anti-VEGF Injections for nAMD Patients in Norway. Clin Ophthalmol. 2023;17:1465-1474. https:\/\/doi.org\/10.2147\/OPTH.S409103 PMID:37256195","DOI":"10.2147\/OPTH.S409103"},{"key":"20137","doi-asserted-by":"crossref","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939-946. https:\/\/doi.org\/10.2147\/OPTH.S100168 PMID:27307696","DOI":"10.2147\/OPTH.S100168"},{"key":"20138","doi-asserted-by":"crossref","unstructured":"Prenner JL, Halperin LS, Rycroft C, et al. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725-31.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.06.023 PMID:26142721","DOI":"10.1016\/j.ajo.2015.06.023"},{"key":"20139","unstructured":"European Medicines Agency. Vabysmo: EPAR - Medicine Overview. 2024. Online https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vabysmo-epar-medicine-overview_en.pdf (Accessed April 2026)"},{"key":"20140","unstructured":"European Medicines Agency. Eylea - Summary of product characteristics. 2024.Online https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf (Accessed April 2026)"},{"key":"20141","doi-asserted-by":"crossref","unstructured":"Zhang Y, Gao S, Li X, et al. Efficacy and safety of anti-vascular endothelial growth factor monotherapies for neovascular age-related macular degeneration: a mixed treatment comparison. Front Pharmacol. 2021;12:797108. https:\/\/doi.org\/10.3389\/fphar.2021.797108 PMID:34992542","DOI":"10.3389\/fphar.2021.797108"},{"key":"20142","unstructured":"Bayer. Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years. 2023.Online https:\/\/www.bayer.com\/media\/en-us\/aflibercept-8-mg-first-to-achieve-sustained-vision-gains-with-more-than-70-of-patients-extended-to-intervals-between-16-and-24-weeks-in-wet-age-related-macular-degeneration-at-two-years\/ (Accessed April 2026)"},{"key":"20143","doi-asserted-by":"crossref","unstructured":"Ozdemir S, Finkelstein E, Lee JJ, et al. Understanding patient preferences in anti-VEGF treatment options for age-related macular degeneration. PLoS One. 2022;17(8):e0272301. https:\/\/doi.org\/10.1371\/journal.pone.0272301 PMID:35951503","DOI":"10.1371\/journal.pone.0272301"},{"key":"20144","doi-asserted-by":"crossref","unstructured":"Ruiz-Medrano J, Pana I, Garc\u00eda-Zamora M, et al. Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice. Int J Retina Vitreous. 2025;12(1):5. https:\/\/doi.org\/10.1186\/s40942-025-00776-0 PMID:41350718","DOI":"10.1186\/s40942-025-00776-0"},{"key":"20145","doi-asserted-by":"crossref","unstructured":"Pina Mar\u00edn B, Gajate Paniagua NM, G\u00f3mez-Bald\u00f3 L, et al. Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: results of the AMD-MANAGE study. Eur J Ophthalmol. 2022;32(1):385-394. https:\/\/doi.org\/10.1177\/11206721211001716 PMID:33719641","DOI":"10.1177\/11206721211001716"},{"key":"20146","doi-asserted-by":"crossref","unstructured":"Abraldes MJ, Calvo P, G\u00e1mez Lechuga M, et al. Burden of disease study of patients with neovascular age-related macular degeneration in Spain. Ophthalmol Ther. 2024;13(7):1925-1935. https:\/\/doi.org\/10.1007\/s40123-024-00960-9 PMID:38771461","DOI":"10.1007\/s40123-024-00960-9"},{"key":"20147","doi-asserted-by":"crossref","unstructured":"Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol. 2006;124(4):529-535. https:\/\/doi.org\/10.1001\/archopht.124.4.529 PMID:16606879","DOI":"10.1001\/archopht.124.4.529"},{"key":"20148","doi-asserted-by":"crossref","unstructured":"Abdalla S, Westborg I, Pulkki-Br\u00e4nnstr\u00f6m AM, et al. Faricimab versus bevacizumab for neovascular age-related macular degeneration: cost analysis based on real-world data from the Swedish Macula Registry. Acta Ophthalmol. 2025;103(1):99-108. https:\/\/doi.org\/10.1111\/aos.16774 PMID:39400438","DOI":"10.1111\/aos.16774"},{"key":"20149","doi-asserted-by":"crossref","unstructured":"Mseke EP, Jessup B, Barnett T. Impact of distance and\/or travel time on healthcare service access in rural and remote areas: a scoping review. J Transp Health. 2024;37:101819. https:\/\/doi.org\/10.1016\/j.jth.2024.101819","DOI":"10.1016\/j.jth.2024.101819"},{"key":"20150","doi-asserted-by":"crossref","unstructured":"Al Dallal S, El Khashab A, Prasan R, et al. Budget impact analysis of intravitreal injections used to treat neovascular age-related macular degeneration and diabetic macular edema in the Dubai healthcare system. Value Health Reg Issues. 2025;46:101083. https:\/\/doi.org\/10.1016\/j.vhri.2025.101083 PMID:39978290","DOI":"10.1016\/j.vhri.2025.101083"},{"key":"20151","doi-asserted-by":"crossref","unstructured":"Lewis JS, Roskruge M, Ah-Chan J. Quantifying cost-savings in the treatment of neovascular age-related macular degeneration in Aotearoa New Zealand. N Z Med J. 2024;137(1604):35-41. https:\/\/doi.org\/10.26635\/6965.6533 PMID:39418603","DOI":"10.26635\/6965.6533"},{"key":"20152","doi-asserted-by":"crossref","unstructured":"Meunier A, Opeifa O, Longworth L, et al. An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective. Eye (Lond). 2024;38(10):1917-1925. https:\/\/doi.org\/10.1038\/s41433-024-03043-y PMID:38555401","DOI":"10.1038\/s41433-024-03043-y"},{"key":"20153","doi-asserted-by":"crossref","unstructured":"Gismero Moreno SM, J\u00f3dar S\u00e1nchez F, Garc\u00eda-Agua Soler N, et al. Model-based pharmacoeconomic analysis of anti-VEGF strategies for neovascular age-related macular degeneration: a value-based comparison of real-world administration approaches. BMJ Open. 2025;15(10):e103539. https:\/\/doi.org\/10.1136\/bmjopen-2025-103539 PMID:41062151","DOI":"10.1136\/bmjopen-2025-103539"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3800\/4548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3800\/4549","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3800\/4548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:31:54Z","timestamp":1783686714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2026.3800","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}